An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice

Active, not recruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

September 23, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Chronic Kidney DiseaseType 2 Diabetes Mellitus
Interventions
DRUG

Finerenone (Kerendia, BAY948862)

Retrospective cohort analysis using the investigator or a delegate at the study site collects secondary/historic data of finerenone usage (patient demographic and clinical characteristics, diagnosis-related, treatment-related, and laboratory data) from clinic specific medical records.

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY